Lotte will invest $3 billion over the next seven years to construct three ‘mega’ plants in Korea with a production capacity of 360,000 L. Contract development manufacturing organization (CDMO) Lotte Biologics said each plant will have the ability to produce 120,000 L of antibody drugs. Furthermore, the plants will have additional expansion plans to include a small-scale incubator for clinical drug substance manufacture and a commercial drug product production facility. The build-out of its first plant will start in the…